173 related articles for article (PubMed ID: 34586532)
1. The Prevalence and Negative Impacts of Substance Use Disorders among People with HIV in the United States: A Real-Time Delphi Survey of Key Stakeholders.
Garner BR; Gotham HJ; Knudsen HK; Zulkiewicz BA; Tueller SJ; Berzofsky M; Donohoe T; Martin EG; Brown LL; Gordon T
AIDS Behav; 2022 Apr; 26(4):1183-1196. PubMed ID: 34586532
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States.
Hartzler B; Dombrowski JC; Crane HM; Eron JJ; Geng EH; Christopher Mathews W; Mayer KH; Moore RD; Mugavero MJ; Napravnik S; Rodriguez B; Donovan DM
AIDS Behav; 2017 Apr; 21(4):1138-1148. PubMed ID: 27738780
[TBL] [Abstract][Full Text] [Related]
3. Utilization of addiction treatment among U.S. adults with history of incarceration and substance use disorders.
Tsai J; Gu X
Addict Sci Clin Pract; 2019 Mar; 14(1):9. PubMed ID: 30836991
[TBL] [Abstract][Full Text] [Related]
4. Persistence/recurrence of and remission from DSM-5 substance use disorders in the United States: Substance-specific and substance-aggregated correlates.
McCabe SE; West BT; Strobbe S; Boyd CJ
J Subst Abuse Treat; 2018 Oct; 93():38-48. PubMed ID: 30126540
[TBL] [Abstract][Full Text] [Related]
5. The Setting-Intervention Fit of Nine Evidence-Based Interventions for Substance Use Disorders Within HIV Service Organizations Across the United States: Results of a National Stakeholder-Engaged Real-Time Delphi Study.
Garner BR; Knudsen HK; Zulkiewicz BA; Tueller SJ; Gotham HJ; Martin EG; Donohoe T; Toro AK; Loyd K; Gordon T
J Acquir Immune Defic Syndr; 2022 Jul; 90(S1):S206-S214. PubMed ID: 35703773
[TBL] [Abstract][Full Text] [Related]
6. Association of Substance Use Disorders with Engagement in Care and Mortality among a Clinical Cohort of People with HIV in Washington, DC.
Doshi RK; Byrne M; Levy M; Varga L; Kuo I; Horberg MA; Castel AD; Monroe AK;
AIDS Behav; 2021 Jul; 25(7):2289-2300. PubMed ID: 33521909
[TBL] [Abstract][Full Text] [Related]
7. Characterizing Help-Seeking Searches for Substance Use Treatment From Google Trends and Assessing Their Use for Infoveillance: Longitudinal Descriptive and Validation Statistical Analysis.
Patton T; Abramovitz D; Johnson D; Leas E; Nobles A; Caputi T; Ayers J; Strathdee S; Bórquez A
J Med Internet Res; 2022 Dec; 24(12):e41527. PubMed ID: 36454620
[TBL] [Abstract][Full Text] [Related]
8. Association Between Diagnoses of Chronic Noncancer Pain, Substance Use Disorder, and HIV-Related Outcomes in People Living With HIV.
Denis CM; Morales KH; Wu Q; Metzger DS; Cheatle MD
J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 2(2):S142-S147. PubMed ID: 31658202
[TBL] [Abstract][Full Text] [Related]
9. High Risk of Alcohol-Impaired Driving in Adults With Comorbid Alcohol and Substance Use Disorders in the U.S. Population.
Roberts W; Moore KE; Pittman BP; Fillmore MT; McKee SA
J Stud Alcohol Drugs; 2019 Jan; 80(1):114-119. PubMed ID: 30807283
[TBL] [Abstract][Full Text] [Related]
10. Testing the effectiveness of a motivational interviewing-based brief intervention for substance use as an adjunct to usual care in community-based AIDS service organizations: study protocol for a multisite randomized controlled trial.
Garner BR; Gotham HJ; Tueller SJ; Ball EL; Kaiser D; Stilen P; Speck K; Vandersloot D; Rieckmann TR; Chaple M; Martin EG; Martino S
Addict Sci Clin Pract; 2017 Nov; 12(1):31. PubMed ID: 29149914
[TBL] [Abstract][Full Text] [Related]
11. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
[TBL] [Abstract][Full Text] [Related]
12. "It's all about asking from those who have walked the path": Patient and stakeholder perspectives on how peers may shift substance use stigma in HIV care in South Africa.
Magidson JF; Rose AL; Regenauer KS; Brooke-Sumner C; Anvari MS; Jack HE; Johnson K; Belus JM; Joska J; Bassett IV; Sibeko G; Myers B
Addict Sci Clin Pract; 2022 Sep; 17(1):52. PubMed ID: 36131304
[TBL] [Abstract][Full Text] [Related]
13. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
14. HIV status and substance use disorder treatment need and utilization among adults in the United States, 2015-2019: Implications for healthcare service provision and integration.
West BS; Krasnova A; Philbin MM; Diaz JE; Kane JC; Mauro PM
J Subst Use Addict Treat; 2024 Jun; 164():209440. PubMed ID: 38880303
[TBL] [Abstract][Full Text] [Related]
15. DSM-5 substance use disorders among adult primary care patients: Results from a multisite study.
Wu LT; McNeely J; Subramaniam GA; Brady KT; Sharma G; VanVeldhuisen P; Zhu H; Schwartz RP
Drug Alcohol Depend; 2017 Oct; 179():42-46. PubMed ID: 28753480
[TBL] [Abstract][Full Text] [Related]
16. Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network.
Wu LT; Ling W; Burchett B; Blazer DG; Yang C; Pan JJ; Reeve BB; Woody GE
Drug Alcohol Depend; 2011 Nov; 118(2-3):186-93. PubMed ID: 21501933
[TBL] [Abstract][Full Text] [Related]
17. Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium.
Lancaster KE; Stockton M; Remch M; Wester CW; Nash D; Brazier E; Adedimeji A; Finlayson R; Freeman A; Hogan B; Kasozi C; Kwobah EK; Kulzer JL; Merati T; Tine J; Poda A; Succi R; Twizere C; Tlali M; Groote PV; Edelman EJ; Parcesepe AM;
Int J Drug Policy; 2024 Feb; 124():104309. PubMed ID: 38228025
[TBL] [Abstract][Full Text] [Related]
18. Alcohol and substance use among transgender women in San Francisco: prevalence and association with human immunodeficiency virus infection.
Santos GM; Rapues J; Wilson EC; Macias O; Packer T; Colfax G; Raymond HF
Drug Alcohol Rev; 2014 May; 33(3):287-95. PubMed ID: 24628655
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample.
Peer K; Rennert L; Lynch KG; Farrer L; Gelernter J; Kranzler HR
Drug Alcohol Depend; 2013 Jan; 127(1-3):215-9. PubMed ID: 22884164
[TBL] [Abstract][Full Text] [Related]
20. Receiving addiction treatment in the US: Do patient demographics, drug of choice, or substance use disorder severity matter?
Johnson K; Rigg KK; Hopkins Eyles C
Int J Drug Policy; 2020 Jan; 75():102583. PubMed ID: 31739148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
